Femasys Inc
Femasys Inc. is a U.S.-based medical technology company developing and commercializing women’s health products, with current focus on FemaSeed and its investigational product FemBloc. The company is still in a development-and-commercialization phase, funding clinical, regulatory, manufacturing, and sales efforts while it works to expand adoption and obtain approval for its pipeline.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCurrently marketed products and related commercialization efforts, including FemaSeed.
Clinical and regulatory development of FemBloc and future product candidates.
Production, sourcing, and supply support needed to make and ship products.
Commercial organization and market-building activities for current and future products.
Customers
The company sells to healthcare customers and distributors that buy women’s health products for clinical use and resale. Its commercial model also depends on physicians, clinics, and other providers that influence adoption of FemaSeed, while FemBloc’s future customer base depends on regulatory approval and market access. International distributors are specifically mentioned as part of the shipping and sales model.
Buy current products shipped directly in the U.S.; they value availability, clinical utility, and reliable fulfillment.
Purchase products for resale under EX-Works terms and extend the company’s reach outside the U.S.
Influence adoption of FemaSeed and potential FemBloc use by choosing products for patient care.
Represents the addressable customer base if FemBloc clears regulatory review and commercialization.
Strategy
The company’s near-term strategy is to fund and complete the pivotal trial for FemBloc while continuing commercialization of FemaSeed. It also needs to build sales, marketing, manufacturing, and regulatory capabilities, which makes capital raising a central strategic priority. Longer term, success depends on converting clinical evidence into approval, market access, and broader product expansion.
Clinical evidence is required to support approval and future commercialization.
Cash on hand is not sufficient to sustain operations and development plans.
Current product sales help establish the platform and support future adoption.
Geography
Q2/2026Femasys is headquartered in the United States and appears operationally centered there, with direct U.S. shipping and commercialization as the core business. The company also serves international distributors, so non-U.S. markets matter for future expansion, but the filings provided do not disclose a country revenue split. Geography is important because U.S. regulatory approval, FDA timing, and domestic commercialization are central to the company’s near-term execution.
Share of the revenue the company reports by geography.
Risks
Femasys faces substantial going-concern and financing risk because management states cash is insufficient to sustain operations without additional capital. The company is also exposed to clinical, regulatory, and commercialization risk: delays or setbacks in the FemBloc trial or FDA review could materially slow or prevent product launch, while Nasdaq listing compliance adds market and financing pressure. As a medical device company, it also faces execution risk around manufacturing, supply continuity, and adoption by providers and distributors.
- Liquidity and going-concern riskImpact: CriticalLikelihood: High
Management says current cash is not sufficient to fund operations and development.
Exposure - Clinical and regulatory approval riskImpact: HighLikelihood: High
FemBloc depends on successful pivotal trial results and FDA review.
Exposure: FemBloc pipeline
- Nasdaq delisting riskImpact: HighLikelihood: High
The company received deficiency notices tied to continued listing requirements.
Exposure: Capital markets access and stock liquidity
- Commercialization and adoption riskImpact: MediumLikelihood: High
Revenue depends on physician, clinic, and distributor uptake of products.
Exposure: FemaSeed and future FemBloc sales
Accounting
Judgemental itemsRevenue is booked when goods ship, so timing around period-end can shift reported sales.
Impact: Quarterly revenue comparability
FOB shipping point and EX-Works terms determine when revenue is recognized.
Impact: Revenue cut-off and returns handling
Non-cash charges are meaningful in operating losses and can distort cash burn analysis.
Impact: Net loss and operating expense presentation
Liquidity constraints may influence valuation allowances, expense timing, and disclosures.
Impact: Financial statement estimates and disclosure risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Evofem Biosciences, Inc.
EVFM · Pharmaceutical Preparations
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Ensysce Biosciences, Inc.
ENSC · Pharmaceutical Preparations
Progyny, Inc.
PGNY · Services-Misc Health & Allied Services, NEC
Last updated: 24/09/2026